Plain-English translation of NCT02435992 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative colitis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested (ozanimod), a new daily oral medication, to see if it could help treat moderate to severe ulcerative colitis. The study followed patients through two phases: an initial treatment phase to see if the medication worked, and then a longer maintenance phase to see if it kept working over time. Researchers compared patients who received the medication to those who received a placebo (a dummy pill with no active ingredient).
Ulcerative colitis is a serious inflammatory bowel condition that causes painful symptoms and can significantly impact quality of life. This medication was being studied to offer patients with moderate to severe disease a new treatment option that might be more effective or better tolerated than existing therapies.
Participants received either the study medication or a placebo as a daily oral pill and were monitored closely during an induction (initial treatment) phase to see if they responded well to the treatment. Those who showed clinical improvement then moved into a maintenance phase, where they continued taking their assigned treatment to see if the benefits lasted over time. Throughout the trial, participants underwent regular medical visits, symptom assessments, and blood tests to monitor their progress and safety.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States